Get the Stockscreener App
86.48
3.51%
-3.15
After Hours:
86.48
Dianthus Therapeutics Inc stock is traded at $86.48, with a volume of 468.43K.
It is down -3.51% in the last 24 hours and down -5.27% over the past month.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
See More
Previous Close:
$89.63
Open:
$88.86
24h Volume:
468.43K
Relative Volume:
0.51
Market Cap:
$4.73B
Revenue:
$1.34M
Net Income/Loss:
$-173.66M
P/E Ratio:
-20.90
EPS:
-4.1385
Net Cash Flow:
$-130.49M
1W Performance:
+0.37%
1M Performance:
-5.27%
6M Performance:
+108.64%
1Y Performance:
+371.02%
1-Day Range:
$86.14
$90.68
1-Week Range:
$80.32
$91.19
52-Week Range:
$16.64
$96.50
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Name
Dianthus Therapeutics Inc
Sector
Industry
Phone
929-999-4055
Address
7 TIMES SQUARE, NEW YORK
Compare DNTH vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
86.48 | 4.90B | 1.34M | -173.66M | -130.49M | -4.1385 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | Wolfe Research | Outperform |
| Mar-10-26 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-14-25 | Initiated | Truist | Buy |
| Jul-02-25 | Initiated | William Blair | Outperform |
| Dec-20-24 | Initiated | TD Cowen | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-26-24 | Initiated | Robert W. Baird | Outperform |
| Jun-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-24 | Initiated | H.C. Wainwright | Buy |
| Feb-15-24 | Initiated | Stifel | Buy |
| Dec-26-23 | Initiated | Jefferies | Buy |
| Nov-22-23 | Initiated | Wedbush | Outperform |
| Oct-30-23 | Initiated | Guggenheim | Buy |
| Sep-28-23 | Initiated | Raymond James | Outperform |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-06-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-20-21 | Resumed | Goldman | Neutral |
| Aug-03-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-21 | Reiterated | B. Riley Securities | Buy |
| Jun-29-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-18-21 | Initiated | B. Riley Securities | Buy |
| Jan-07-21 | Initiated | Mizuho | Buy |
| Jun-08-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-25-19 | Downgrade | Goldman | Buy → Neutral |
| Mar-15-19 | Initiated | Raymond James | Outperform |
View All
Dianthus Therapeutics Inc Stock (DNTH) Latest News
Dianthus (DNTH) director receives 6,090 options vesting by 2027 - Stock Titan
Dianthus Therapeutics (DNTH) director receives grant of 6,090 stock options - Stock Titan
Director at Dianthus Therapeutics (DNTH) granted 6,090 stock options - Stock Titan
Dianthus (DNTH) director Jonathan Violin receives grant of 6,090 stock options - Stock Titan
Director Paula Soteropoulos gets 6,090 DNTH options in new award - Stock Titan
Dianthus (NASDAQ: DNTH) investors approve board, pay and auditor - Stock Titan
DNTH News | DIANTHUS THERAPEUTICS INC (NASDAQ:DNTH) - ChartMill
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish - AOL.com
Assessing Dianthus Therapeutics (DNTH) Valuation After LBL-047 Autoimmune Focus Partnership And Capital Raise - Yahoo Finance
Strength seen in Dianthus Therapeutics, Inc. (DNTH): Can its 5.6% jump turn into more strength? - MSN
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally - sharewise.com
Dianthus Therapeutics CFO sold 8,224 shares worth $739,000. - Pluang
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally - The Motley Fool
RA Capital group reports 2,611,733 Dianthus shares (DNTH) - Stock Titan
Point72 reports 643,599 shares (1.2%) in Dianthus Therapeutics (DNTH) - Stock Titan
Sirenia Capital (DNTH) discloses 5.3% stake including 500K options - Stock Titan
Wellington group reports 4.77% stake in Dianthus (NASDAQ: DNTH) - Stock Titan
Tango Therapeutics is the best performing healthcare stock in March - MSN
Octagon entities disclose 1.95M-share stake in Dianthus Therapeutics (DNTH) - Stock Titan
Vanguard Group Inc. Increases Stock Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
A Quick Look at Today's Ratings for Dianthus Therapeutics(DNTH.US), With a Forecast Between $65.2 to $200 - Moomoo
TradingKey - TradingKey
Dianthus Therapeutics (DNTH) director exercises options, sells 599 shares under 10b5-1 plan - Stock Titan
Evercore Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Raises Target Price to $120 - Moomoo
UBS Group AG Acquires 469,547 Shares of Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Rating of "Buy" by Brokerages - MarketBeat
Number of shareholders of Dianthus Therapeutics, Inc. – NASDAQ:DNTH - TradingView
Number of shareholders of Dianthus Therapeutics, Inc. – SWB:87E - TradingView
LifeSci Capital Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $125 - Moomoo
Dianthus Therapeutics (NASDAQ:DNTH) Rating Increased to Hold at Wall Street Zen - MarketBeat
Q2 EPS Forecast for Dianthus Therapeutics Raised by Analyst - MarketBeat
Dianthus Therapeutics, Inc. (DNTH) Stock Analysis: 47.87% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Raymond James Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Raises Target Price to $125 - Moomoo
Truist Financial Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Announces Target Price $110 - Moomoo
A Quick Look at Today's Ratings for Dianthus Therapeutics(DNTH.US), With a Forecast Between $125 to $200 - Moomoo
H.C. Wainwright Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $130 - Moomoo
Wedbush Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price - MarketBeat
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results - The Manila Times
Dianthus Therapeutics (NASDAQ:DNTH) Releases Earnings Results, Beats Expectations By $0.25 EPS - MarketBeat
Dianthus Therapeutics, Inc. (DNTH) reports Q1 loss, lags revenue estimates - MSN
MSN Money - MSN
Dianthus Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Earnings Flash (DNTH) Dianthus Therapeutics, Inc. Reports Q1 Revenue $463K, vs. FactSet Est of $404K - marketscreener.com
Dianthus Therapeutics Q1 net loss widens on higher expenses - TradingView
Dianthus Therapeutics (NASDAQ: DNTH) builds $1.1B cash to fund autoimmune pipeline - Stock Titan
Dianthus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Dianthus got 20 responders before 40 patients in CIDP trial - Stock Titan
Dianthus (Nasdaq: DNTH) raises $719M, ends Q1 2026 with $1.2B cash - Stock Titan
Dianthus Therapeutics Inc Stock (DNTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):